

Supporting information for

**Design of primary amine functionalized polymer containing chiral
isosorbide in the main chain for the asymmetric synthesis of
isoquinuclidine derivatives**

K. Hiba and K. Sreekumar*

Department of Applied Chemistry, Cochin University of Science and Technology,
Kochi-682022, India.

E-mail: K. Sreekumar- kskpolymer.cusat@gmail.com




Figure S1 ^1H NMR spectrum of Chiral-ISO-PECH




Figure S2 ^{13}C NMR spectrum of Chiral-ISO-PECH




Figure S3 TG/DTG plot of Chiral-ISO-PECH




Figure S4 ¹H NMR spectrum of Chiral-ISO-PECH-Amine





Figure S5 ^{13}C NMR spectrum of Chiral-ISO-PECH-Amine


Analytical data of synthesized Isoquinuclidine derivatives

3-exo-(4-Methoxyphenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (4a)




Brown waxy solid; GC-MS (M^+): 307; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.51-7.24 (m, 4H), 7.09-6.78 (m, 1H), 6.63 (d, $J = 6.7$ Hz, 2H), 6.54 (d, $J = 8.2$ Hz, 2H), 4.84-4.65 (m, 1H), 4.60-4.47 (m, 1H), 3.76 (s, 3H), 2.81-2.59 (m, 2H), 2.38-2.31 (m, 2H), 2.19-2.10 (m, 1H), 2.07-1.86 (m, 1H), 1.83-1.65 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 193.1, 131.5, 129.1, 127.2, 117.7, 114.2, 113.1, 83.3, 61.9, 55.3, 51.2, 48.2, 42.3, 29.7, 26.0, 16.3.

3-endo-(4-Methoxyphenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5a)¹




Brown waxy solid; GC-MS (M^+): 307; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.25-7.10 (m, 5H), 6.84 (d, $J = 8.4$, 2H), 6.67 (d, $J = 8.4$, 2H), 4.61-4.59 (m, 1H), 4.55-4.47 (m, 1H), 3.77 (s, 3H), 2.80-1.50 (m, 7H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 212.1, 158.9, 148.2, 133.7, 131.7, 129.3, 126.7, 117.7, 114.5, 114.3, 113.3, 65.4, 55.2, 52.3, 48.5, 45.9, 29.7, 22.7, 22.5; enantiomeric excess: 73 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 10.9$ min, minor enantiomer $R_t = 15.4$ min.

3-exo-Phenyl-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (4b)²




Brown solid; m. p. 112-113 °C (lit.² 112-113 °C); GC-MS (M^+): 277; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.39-7.33 m, 4H), 7.28-7.25 (m, 1H), 7.14-7.10 (m, 2H), 6.68 (t, $J = 7.2$ Hz, 1H), 6.57 (d, $J = 8.4$ Hz, 2H), 4.75 (d, $J = 2.0$ Hz, 1H), 4.53-4.52 (m, 1H), 2.77-2.68 (m, 2H), 2.42-2.37 (m, 1H), 2.29-2.19 (m, 1H), 1.95-1.84 (m, 1H), 1.74-1.60 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 213.1, 147.9, 139.8, 129.1, 128.6, 127.2, 125.9, 117.5, 112.9, 62.3, 51.0, 48.2, 42.3, 26.0, 16.4.

3-endo-Phenyl-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5b)²




Brown solid; m. p. 121-122 °C (lit.² 120-121 °C); GC-MS (M^+): 277; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.27-7.25 (m, 4H), 7.18-7.15 (m, 1H), 7.15-7.08 (m, 2H), 6.69 (t, $J = 7.4$ Hz, 1H), 6.62-6.58 (m, 2H), 4.61 (d, $J = 2.7$ Hz, 1H), 4.47 (m, 1H), 2.75- 2.67 (m, 2H), 2.42-2.37 (m, 1H), 2.27-2.17 (m, 1H), 2.10-2.01 (m, 1H), 1.98-1.92 (m, 1H), 1.70-1.63 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 211.3, 147.7, 141.4, 128.9, 128.6, 127.1, 125.2, 117.3, 112.9, 65.6, 52.0, 48.3, 45.6, 22.5, 22.4; enantiomeric excess: 22 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 7.6$ min, minor enantiomer $R_t = 7.1$ min.

3-exo-(4-Chlorophenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (4c)²




Brown solid; m. p. 138-140 °C (lit.² 138-139 °C); GC-MS (M^+): 311; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.32 (m, 4H), 7.14-7.10 (m, 2H), 6.70 (t, $J = 7.4$ Hz, 1H), 6.56-6.54 (m, 2H), 4.72 (d, $J = 2.8$ Hz, 1H), 4.52-4.51 (m, 1H), 2.76-2.70 (m, 1H), 2.66-2.64 (m, 1H), 2.39(dd, $J = 18.8$ Hz, 1.7 Hz, 1H), 2.25-2.16 (m, 1H), 1.93-1.85 (m, 1H), 1.70-1.59 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 212.6, 147.6, 138.4, 132.9, 129.1, 128.8, 127.3, 117.8, 112.9, 61.8, 50.7, 48.1, 42.2, 26.0, 16.3.

3-endo-(4-Chlorophenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5c)²




Brown solid; m. p. 154-155 °C (lit.² 156-157 °C); GC-MS (M^+): 311; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.27-7.22 (m, 4H), 7.20-7.14 (m, 2H), 6.76-6.72 (m, 1H), 6.62-6.60 (m, 2H), 4.61 (d, $J = 2.8$ Hz, 1H), 4.53-4.52 (m, 1H), 2.76-2.68 (m, 2H), 2.47 (dd, $J = 18.8$ Hz, 2.6 Hz, 1H), 2.31-2.22 (m, 1H), 2.16-2.00 (m, 2H), 1.78-1.70 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 210.7, 147.3, 139.8, 132.7, 128.8, 128.7, 126.6, 117.6, 112.9, 64.9, 51.8, 48.3, 45.6, 22.4, 22.2; enantiomeric excess: 92 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 9.2$ min, minor enantiomer $R_t = 7.8$ min.

3-exo-(4-Bromophenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (4d)²




Brown solid; m. p. 123-124 °C (lit.² 125-126 °C); GC-MS (M^+): 356; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.47 (d, $J = 8.4$ Hz, 2H), 7.26 (d, $J = 8.0$ Hz, 2H), 7.14-7.10 (m, 2H), 6.70 (t, $J = 7.4$ Hz, 1H), 6.55 (d, $J = 8.2$ Hz, 2H), 4.70 (d, $J = 2.6$ Hz, 1H), 4.52-4.51 (m, 1H), 2.76-2.70 (m, 1H), 2.66-2.64 (m, 1H), 2.39 (dd, $J = 18.8$ Hz, 1.6 Hz, 1H), 2.24-2.15 (m, 1H), 1.94-1.86 (m, 1H), 1.68-1.60 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 212.5, 147.6, 139.0, 131.7, 129.1, 127.7, 121.0, 117.8, 112.9, 61.8, 50.7, 48.2, 42.2, 26.0, 16.3.

3-endo-(4-Bromophenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5d)²




Brown solid; m. p. 158-159 °C (lit.² 157-158 °C); GC-MS (M^+): 356; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.41 (d, $J = 8.3$ Hz, 2H), 7.18-7.14 (m, 4H), 6.74 (t, $J = 7.2$ Hz, 1H), 6.61 (d, $J = 8.2$ Hz, 2H), 4.59 (d, $J = 2.2$ Hz, 1H), 4.53-4.52 (m, 1H), 2.75-2.68 (m, 2H), 2.46 (dd, $J = 18.8$ Hz, 1.6 Hz, 1H), 2.29-2.24 (m, 1H), 2.15-2.01 (m, 2H), 1.78-1.71 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 210.9, 147.6, 140.6, 131.9, 129.2, 127.2, 121.2, 117.9, 113.2, 65.3, 52.0, 48.6, 45.9, 22.7, 22.6; enantiomeric excess: 41 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 9.9$ min, minor enantiomer $R_t = 9.6$ min.

3-endo-(3,4-Dimethoxyphenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5e)




Brown waxy solid; GC-MS (M^+): 337; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.11 (t, $J = 7.8$ Hz, 2H), 6.79-6.60 (m, 6H), 4.52 (m, 1H), 4.47 (m, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 2.71-2.67 (m, 2H), 2.42-2.10 (m, 1H), 1.99-1.94 (m, 1H), 1.69-1.65 (m, 2H), 1.38-1.34 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 211.0, 148.3, 147.2, 133.3, 128.2, 116.8, 116.6, 112.4, 110.5, 107.6, 64.8, 54.9, 54.8, 51.3, 47.5, 44.9, 30.9, 28.7, 21.6, 21.5, 13.1; enantiomeric excess: 78 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 10.9$ min, minor enantiomer $R_t = 15.5$ min.

3-endo-(4-Nitrophenyl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5f)³




Yellow liquid; GC-MS (M^+): 322; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 8.19 (d, $J = 8.4$ Hz, 2H), 7.49 (d, $J = 8.4$ Hz, 2H), 7.20 (t, $J = 7.5$ Hz, 2H), 6.79 (t, $J = 7.5$ Hz, 1H), 6.61 (d, $J = 7.5$ Hz, 2H), 4.75 (d, $J = 2.4$ Hz, 1H), 4.60 (m, 1H), 2.81-2.70 (m, 2H), 2.52 (d, $J = 18.9$ Hz, 1H), 2.31-2.05 (m, 3H), 1.86-1.76 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 210.6, 149.2, 147.3, 129.5, 126.7, 124.4, 123.8, 118.6, 113.5, 65.3, 51.9, 48.8, 45.9, 22.6, 22.4; enantiomeric excess: 34 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 7.3$ min, minor enantiomer $R_t = 8.1$ min.

3-exo-(Furan-2-yl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (4g)




Brown waxy solid; GC-MS (M^+): 267; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.37-7.33 (m, 1H), 7.19-7.13 (m, 1H), 7.11-6.99 (m, 3H), 6.70-6.61 (m, 1H), 6.60-6.28 (m, 2H), 4.73 (m, 1H), 4.37 (m, 1H), 2.96-2.91 (m, 1H), 2.81-2.63 (m, 1H), 2.35-2.17 (m, 1H), 1.87-1.82 (m, 1H), 1.66-1.64 (m, 1H), 1.77-1.72 (m, 1H), 1.36-1.34 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 212.8, 153.2, 148.1, 142.3, 129.4, 118.0, 113.0, 110.5, 108.0, 57.7, 48.1, 42.2, 29.7, 26.0, 17.3.

3-endo-(Furan-2-yl)-2-phenyl-2-azabicyclo[2.2.2]octan-5-one (5g)




Brown waxy solid; GC-MS (M^+): 267; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.28 (s, 1H), 7.19-7.14 (m, 3H), 6.69-6.67 (m, 2H), 6.19 (s, 1H), 6.11 (s, 1H), 4.62 (m, 1H), 4.37 (m, 1H), 2.84-2.73 (m, 2H), 2.53-2.42 (m, 1H), 2.38-1.94 (m, 2H), 1.64-1.34 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 211.9, 154.7, 148.1, 142.4, 129.3, 118.0, 113.1, 106.8, 60.3, 49.2, 48.4, 45.9, 29.7, 22.4, 21.9; enantiomeric excess: 62 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min^{-1} , 254 nm): major enantiomer $R_t = 6.1$ min, minor enantiomer $R_t = 5.6$ min.

2-exo-(4-Methoxyphenyl)-3-phenyl-2-azabicyclo[2,2,2]octan-5-one (4h)²




Yellow solid; m. p. 111-112 °C (lit.² 110-111 °C); GC-MS (M^+): 307; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.41-7.32 (m, 4H), 7.30-7.22 (m, 1H), 6.74-6.66 (m, 2H), 6.56-6.49 (m, 2H), 4.68 (d, $J = 2.4$ Hz, 1H), 4.42-4.40 (m, 1H), 3.67 (s, 3H), 2.77-2.71 (m, 1H), 2.66-2.63 (m, 1H), 2.38-2.33 (m, 1H), 2.30-2.18 (m, 1H), 1.92-1.80 (m, 1H), 1.75-1.67 (m, 1H), 1.65-1.54 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 236.3, 174.5, 165.2, 163.0, 151.4, 149.9, 148.8, 137.4, 136.9, 85.4, 78.4, 73.8, 71.6, 64.7, 49.1, 39.2.

2-endo-(4-Methoxyphenyl)-3-phenyl-2-azabicyclo[2,2,2]octan-5-one (5h)²



Yellow solid; m. p. 201-202 °C (lit.² 200-201 °C); GC-MS (M^+): 307; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.26-7.25 (m, 4H), 7.18-7.16 (m, 1H), 6.71 (d, $J = 8.8$ Hz, 2H), 6.58 (d, $J = 8.8$ Hz, 2H), 4.54 (d, $J = 2.4$ Hz, 1H), 4.38-4.36 (m, 1H), 3.65 (s, 3H), 2.74- 2.72 (m, 2H), 2.43-2.38 (m, 1H), 2.20-2.17 (m, 1H), 2.08-2.00 (m, 1H), 1.99-1.93 (m, 1H), 1.70-1.65 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ (ppm) 211.4, 151.6, 142.1, 141.9, 128.5, 127.1, 125.3, 114.4, 114.3, 66.0, 55.4, 52.1, 49.2, 45.9, 22.5, 22.2; enantiomeric excess: 70 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 8.9$ min, minor enantiomer $R_t = 11.3$ min.


2-exo-(4-Bromophenyl)-3-phenyl-2-azabicyclo[2.2.2]octan-5-one (4i)²



Pale yellow solid; m. p. 158-160 °C (lit.² 158-159 °C); GC-MS (M^+): 356; ^1H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.39-7.32 (m, 4H), 7.30-7.28 (m, 1H), 7.18 (d, $J = 9.0$ Hz, 2H), 6.44 (d, $J = 9.0$ Hz, 2H), 4.70 (d, $J = 2.0$ Hz, 1H), 4.48-4.47 (m, 1H), 2.75- 2.65 (m, 2H), 2.43-2.39 (m, 1H), 2.29-2.21 (m, 1H), 1.94-1.86 (m, 1H), 1.70-1.62 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz):

δ (ppm) 212.7, 146.8, 139.1, 131.8, 128.7, 127.4, 125.8, 114.5, 109.5, 62.2, 50.9, 48.4, 42.3, 25.9, 16.3.


2-endo-(4-Bromophenyl)-3-phenyl-2-azabicyclo[2.2.2]octan-5-one (5i)²



Pale yellow solid; m. p. 119-121 °C (lit.² 120-121 °C); GC-MS (M^+): 356; ¹H NMR ($CDCl_3$, 400 MHz): δ (ppm) 7.30-7.26 (m, 2H), 7.23-7.17 (m, 5H), 6.51-6.47 (m, 2H), 4.58 (d, $J = 2.4$ Hz, 1H), 4.45-4.44 (m, 1H), 2.78-2.70 (m, 2H), 2.46-2.41 (m, 1H), 2.24-2.16 (m, 1H), 2.15-1.97 (m, 2H), 1.75-1.68 (m, 1H); ¹³C NMR ($CDCl_3$, 100 MHz): δ (ppm) 210.8, 146.7, 140.8, 131.7, 128.8, 127.5, 125.7, 116.4, 114.8, 65.7, 52.0, 48.8, 45.7, 22.8, 22.5; enantiomeric excess: 21 %, determined by HPLC (Chiralpak IB-3 column, hexane:isopropanol (90:10), flow rate 1.0 mL min⁻¹, 254 nm): major enantiomer $R_t = 9.3$ min, minor enantiomer $R_t = 10.5$ min.

References


1. V. I. Maleev, V. S. Tat'yana, L. V. Yashkina, A. F. Mkrtchyan, A. S. Saghyan, M. M. Il'in and D. A. Chusov, *Tetrahedron: Asymmetry*, 2013, **24**, 178.
2. L. Huang, J. P. Chen, C. Jin and W. K. Su, *Chin. Chem. Lett.*, 2013, **24**, 347.
3. D. Borkin, E. Morzhina, S. Datta, A. Rudnitskaya, A., Sood, M. Török and B. Török, *Org. Biomol. Chem.*, 2011, **9**, 1394.



Gas chromatogram of 4a and 5a mixture

Abundance


TIC: ME4.D\data.ms



Time-->

Gas chromatogram of 4a


Abundance



Mass spectrum of 4a


Abundance

TIC: ME10.D\data.ms




Time-->


Gas chromatogram of 5a




Mass spectrum of 5a




HPLC profile of 5a




¹H NMR spectrum of 4a




¹³C NMR spectrum of 4a



¹H NMR spectrum of 5a




¹³C NMR spectrum of 5a




Gas chromatogram of 4b and 5b mixture

Abundance



Gas chromatogram of 4b


Abundance



Mass spectrum of 4b

Abundance


TIC: BE12.D\data.ms



Time-->

Gas chromatogram of 5b


Abundance




m/z-->

Mass spectrum of 5b


mAU




HPLC profile of 5b




¹H NMR spectrum of 4b



¹³C NMR spectrum of 4b




¹H NMR spectrum of 5b



¹³C NMR spectrum of 5b


Abundance



Gas chromatogram of 4c and 5c mixture


Abundance

TIC: 4CL.D\data.ms



Gas chromatogram of 4c


Abundance



Mass spectrum of 4c


Abundance

TIC: 12CL.D\data.ms




Time-->


Gas chromatogram of 5c




Mass spectrum of 5c




HPLC profile of 5c




¹H NMR spectrum of 4c



¹³C NMR spectrum of 4c




¹H NMR spectrum of 5c




¹³C NMR spectrum of 5c

Abundance



Gas chromatogram of 4d and 5d mixture


Abundance



Time-->

Gas chromatogram of 4d


Abundance



Mass spectrum of 4d


Abundance

TIC: BR8.D\data.ms



Gas chromatogram of 5d


Abundance




m/z-->

Mass spectrum of 5d


mAU




HPLC profile of 5d



¹H NMR spectrum of 4d



¹³C NMR spectrum of 4d



^1H NMR spectrum of 5d


-211.5

~147.9
~140.9
~132.2
~129.4
~127.5
~118.2
~115.2
~113.5

-65.4

~52.1
~48.7
~46.0


~22.7
~22.5



^{13}C NMR spectrum of 5d

Abundance


TIC: BVB.D\data.ms



Time-->


Gas chromatogram of 4e

Abundance




Mass spectrum of 4e

Abundance




Time-->



Gas chromatogram of 5e




Mass spectrum of 5e



HPLC profile of 5e




Abundance



Time-->


Gas chromatogram of 4f and 5f mixture

Abundance




Mass spectrum of 4f

Abundance




Mass spectrum of 5f

mAU



HPLC profile of 5f


Abundance




Time-->

Gas chromatogram of 4g and 5g mixture

Abundance




Abundance




Mass spectrum of 4g

Abundance




Gas chromatogram of 5g

Abundance







Mass spectrum of 5g

mAU




HPLC profile of 5g





Abundance

TIC: AZ2M1.D\data.ms




Time-->

Gas chromatogram of 4h and 5h mixture

Abundance


TIC: ME3.D\data.ms



Time-->

Gas chromatogram of 4h


Abundance



Mass spectrum of 4h


Abundance

TIC: ME8.D\data.ms



Gas chromatogram of 5h


Abundance



m/z-->


Mass spectrum of 5h

mAU




HPLC profile of 5h

Abundance




Gas chromatogram of 4i and 5i mixture

Abundance




Gas chromatogram of 4i

Abundance



Mass spectrum of 4i


Abundance



Time-->


Gas chromatogram of 5i

Abundance




Mass spectrum of 5i


mAU




HPLC profile of 5i




¹H NMR spectrum of 4i



¹³C NMR spectrum of 4i



¹H NMR spectrum of 5i



¹³C NMR spectrum of 5i